Summary

US Inhaled Nitric Oxide Market is valued approximately at USD 315.31 million in 2023 and is anticipated to grow with a healthy growth rate of more than 7.70% over the forecast period 2024-2032. Inhaled nitric oxide (iNO) is a therapeutic gas used in medicine to improve oxygenation in individuals facing specific respiratory challenges. It works by dilating blood vessels in the lungs, enhancing blood flow to areas critical for efficient oxygen exchange. Nitric oxide is naturally produced in the body and helps regulate blood pressure through vasodilation. iNO specifically targets blood vessels near oxygen-rich lung regions, promoting relaxation and increased blood flow to enhance oxygen uptake by red blood cells. This targeted approach is crucial for treating conditions like neonatal respiratory distress, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), among others. Accordingly, iNO plays a vital role in managing vascular and oxygenation issues, especially in neonatal and critical care scenarios. The increasing technological advancements in iNO delivery systems and monitoring technologies is a key trend that is supporting the growth of the US Inhaled Nitric Oxide Market. Adult patient iNO treatment administration is becoming safer and easier because to advancements in iNO delivery methods and monitoring technology. These developments broaden the range of iNO uses in adult respiratory care and enhance treatment results.

The incidence of conditions like neonatal respiratory disorder, tuberculosis, and ARDS has been on the rise. According to data from the Asthma and Allergy Foundation of America in April 2022, over 27 million individuals in the United States are affected by asthma, representing approximately 1 in every 12 people. This prevalence is witnessing a surge in demand for inhaled nitric oxide, fueling the regional US market expansion. Additionally, the increasing number of initiatives led by government and non-governmental organizations is also bolstering the US Inhaled Nitric Oxide Market growth during the estimated period. For instance, in 2021, The Centers for Disease Control and Prevention’s NACP allocated funds for educating patients with asthma. These initiatives are expected to raise awareness about asthma, leading to greater adoption of inhaled nitric oxide for managing asthma symptoms, thus propelling market growth in the region. Furthermore, the United States boasts a robust healthcare infrastructure with advanced technological capabilities, fostering the development and adoption of innovative iNO delivery systems and therapies. Ongoing clinical research and strong evidence supporting the efficacy of iNO therapy further contribute to its increasing utilization in clinical settings, supported by regulatory approvals from agencies such as the FDA. However, stringent application norms across various regions, along with high costs incurred with the procedure is expected to hinder the market growth between 2022 and 2032.
Major market player included in this report are:
Matheson Tri-Gas Inc. (United States)
Nu-Med Plus Inc. (United States)
Perma Pure LLC (United States)
Praxair Distribution Inc. (United States)
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Application
Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease
Acute Respiratory Distress Syndrome
Others

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. US Inhaled Nitric Oxide Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Inhaled Nitric Oxide Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Application
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Inhaled Nitric Oxide Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Inhaled Nitric Oxide Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Inhaled Nitric Oxide Market Size & Forecasts by Application 2022-2032
5.1. Neonatal Respiratory Treatment
5.2. Chronic Obstructive Pulmonary Disease
5.3. Acute Respiratory Distress Syndrome
5.4. Others
Chapter 6. Competitive Intelligence
6.1. Key Company SWOT Analysis
6.1.1. Company 1
6.1.2. Company 2
6.1.3. Company 3
6.2. Top Market Strategies
6.3. Company Profiles
6.3.1. Matheson Tri-Gas Inc. (United States)
6.3.1.1. Key Information
6.3.1.2. Overview
6.3.1.3. Financial (Subject to Data Availability)
6.3.1.4. Product Summary
6.3.1.5. Market Strategies
6.3.2. Nu-Med Plus Inc. (United States)
6.3.3. Perma Pure LLC (United States)
6.3.4. Praxair Distribution Inc. (United States)
6.3.5. Company 5
6.3.6. Company 6
6.3.7. Company 7
6.3.8. Company 8
6.3.9. Company 9
6.3.10. Company 10
Chapter 7. Research Process
7.1. Research Process
7.1.1. Data Mining
7.1.2. Analysis
7.1.3. Market Estimation
7.1.4. Validation
7.1.5. Publishing
7.2. Research Attributes